MG
LXRX icon

Michael Gelband’s Lexicon Pharmaceuticals LXRX Stock Holding History

Michael Gelband’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-37,430
Closed -$58.4K – 1856
2026
Q1 		$58.4K Sell
37,430
-231,003
-86% -$336K ﹤0.01% 1457
2025
Q4 		$309K Buy
+268,433
New +$369K ﹤0.01% 1306
2025
Q3 		– Sell
-12,241
Closed -$12K – 1819
2025
Q2 		$12K Buy
+12,241
New +$7.93K ﹤0.01% 1393
2024
Q2 		– Sell
-319,058
Closed -$766K – 1784
2024
Q1 		$766K Buy
+319,058
New +$685K 0.01% 1030
2023
Q2 		– Sell
-15,536
Closed -$38K – 2085
2023
Q1 		$38K Buy
+15,536
New +$35.6K ﹤0.01% 1672
2022
Q2 		– Sell
-16,301
Closed -$34K – 2226
2022
Q1 		$34K Sell
16,301
-17,600
-52% -$48.8K ﹤0.01% 2088
2021
Q4 		$134K Buy
33,901
+9,700
+40% +$47.1K ﹤0.01% 1904
2021
Q3 		$116K Sell
24,201
-7,637
-24% -$31.3K ﹤0.01% 1884
2021
Q2 		$146K Sell
31,838
-53,777
-63% -$259K ﹤0.01% 2065
2021
Q1 		$503K Buy
+85,615
New +$593K 0.01% 1342
2020
Q3 		– Sell
-25,622
Closed -$51K – 2029
2020
Q2 		$51K Buy
+25,622
New +$50.2K ﹤0.01% 1681
2019
Q4 		– Sell
-136,840
Closed -$412K – 1728
2019
Q3 		$412K Buy
+136,840
New +$424K 0.01% 742

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Michael Gelband's LXRX Position: Q2 2026 in Review

Michael Gelband sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2026, closing a stake of 37,430 shares — an estimated $58.4K sold.

Michael Gelband first reported a position in LXRX in Q3 2019 and held it in 12 quarters. The position peaked at $766K in Q1 2024. 148 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Michael Gelband reported no remaining Lexicon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 37,430 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $58.4K.
  • Michael Gelband first reported a position in Lexicon Pharmaceuticals in Q3 2019 and held it in 12 quarters.
  • Michael Gelband's Lexicon Pharmaceuticals position peaked at $766K in Q1 2024.
  • 148 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.